
|Articles|November 26, 2007
FDA approves Combigan
The FDA has approved Allergan's Combigan for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Advertisement
The FDA has approved Allergan's Combigan for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP.
Combigan (brimonidine tartrate/timolol maleate) ophthalmic solution is an alpha adrenergic receptor agonist with a beta adrenergic receptor inhibitor. In pivotal 12-month trials, the drug significantly reduced mean IOP by up to 7.6 mmHg from baseline and was found to be well tolerated.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
BL1332 misses primary end point in phase 2 post-PRK ocular pain study
2
FLORetina-ICOOR 2026: AI moves from the image to the trial, the clinic, and the operating room
3
Water-soluble CBD eye drops lower IOP and dampen corneal sensitivity in glaucoma mouse model
4
Q&A: GLP-1 RAs and NAION, the case for a baseline exam
5











